전신성 홍반성 루푸스 환자에서 Obinutuzumab의 효능 및 안전성을 평가하기 위한 연구 (ALLEGORY)
전신성 홍반성 루푸스 환자에서 오비누투주맙의 효능 및 안전성을 평가하기 위한 3상, 무작위, 이중맹검, 위약 대조, 다기관 연구
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Cape Town, 남아프리카, 7500
- Panorama Medical Center
-
Pretoria, 남아프리카, 0002
- Emmed Research
-
Somerset West, 남아프리카, 7130
- Clinical Trials Network Helderberg
-
Umhlanga, 남아프리카, 4319
- Dr Asokan Naidoo
-
-
-
-
-
Auckland, 뉴질랜드, 2025
- Middlemore Hospital
-
Wellington, 뉴질랜드, 0621
- Wellington Hospital
-
-
-
-
Bashkortostan Republic
-
Ufa, Bashkortostan Republic, 러시아 제국, 450005
- Republican clinical hospital named after G.G. Kuvatov
-
-
Moscow Oblast
-
Moscow, Moscow Oblast, 러시아 제국, 115522
- Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, 러시아 제국, 197341
- FGBU ?Federal Medical and Research Center named after V.A.Almazov? Russian Ministry of Health
-
-
-
-
Coahuila
-
Torreón, Coahuila, 멕시코, 27000
- Centro de Investigacion Alberto Bazzoni S.A. de C.V.
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, 멕시코, 21100
- Unidad de Reumatologia Rehabilitacion Integral
-
-
Mexico CITY (federal District)
-
Mexico City, Mexico CITY (federal District), 멕시코, 11850
- Centro de Investigación y Tratamiento Reumatológico S.C.
-
-
Nuevo León
-
Monterrey, Nuevo León, 멕시코, 64460
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
-
-
-
Alabama
-
Anniston, Alabama, 미국, 36207
- Pinnacle Research Group
-
-
Arkansas
-
Searcy, Arkansas, 미국, 72143
- Unity Health - White County Medical Center- Rheumatology
-
-
California
-
Fullerton, California, 미국, 92835
- Providence Medical Foundation
-
-
Florida
-
Aventura, Florida, 미국, 33180
- Arthritis & Rheumatism
-
-
Michigan
-
Lansing, Michigan, 미국, 48911
- Great Lakes Center of Rheumatology
-
Troy, Michigan, 미국, 48047
- Clinical Research Institute of Michigan, LLC
-
-
New York
-
Great Neck, New York, 미국, 11021
- Northwell Health Division of Rheumatology
-
New York, New York, 미국, 10032
- Columbia University Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- Joint & Muscle Research Institute
-
-
Ohio
-
Columbus, Ohio, 미국, 43212
- The Ohio State University Wexner Medical Center
-
Middleburg Heights, Ohio, 미국, 44130
- Paramount Medical Research & Consulting, LLC
-
-
Texas
-
Colleyville, Texas, 미국, 76034
- Precision Comprehensive Clinical Research Solutions
-
El Paso, Texas, 미국, 79902
- Texas Arthritis Center
-
Houston, Texas, 미국, 77054
- Prolato Clinical Research Center
-
-
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, 브라질, 40150-150
- Ser Servicos Especializados Em Reumatologia
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, 브라질, 30130-100
- Hospital das Clinicas - UFMG
-
Belo Horizonte, Minas Gerais, 브라질, 30150-221
- Santa Casa de Misericordia
-
Juiz de Fora, Minas Gerais, 브라질, 36010-570
- Centro Mineiro de Pesquisa - CMIP
-
-
Paraná
-
Curtiba, Paraná, 브라질, 80030-110
- Centro de Estudos em Terapias Inovadoras ? CETI
-
-
São Paulo
-
Ribeirão Preto, São Paulo, 브라질, 14051-140
- Hospital das Clinicas - FMUSP Ribeirao Preto
-
São Bernardo do Campo, São Paulo, 브라질, 09715-090
- Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*
-
-
-
-
-
Barcelona, 스페인, 08035
- Hospital Universitario Vall d'Hebron
-
Madrid, 스페인, 28007
- Hospital General Universitario Gregorio Marañon
-
-
-
-
-
Buenos Aires, 아르헨티나, C1015ABO
- Organizacion Medica de Investigacion
-
Buenos Aires, 아르헨티나, C1111AAJ
- DOM Centro de Reumatología
-
San Miguel, 아르헨티나, T4000AXL
- Centro de Investigaciones Médicas Tucuman
-
-
-
-
-
Cambridge, 영국, CB2 2QQ
- Addenbrooke'S Hospital
-
Leeds, 영국, LS1 3EX
- Chapel Allerton Hospital
-
London, 영국, SE1 9RT
- Guy's Hospital
-
London, 영국, NW3 2QG
- Royal Free Hospital
-
Manchester, 영국, M13 9WL
- Manchester Royal Infirmary
-
-
-
-
Lazio
-
Rome, Lazio, 이탈리아, 00168
- Policlinico Universitario Agostino Gemelli
-
-
Lombardy
-
Milan, Lombardy, 이탈리아, 20132
- IRCCS S. Raffaele
-
-
Tuscany
-
Pisa, Tuscany, 이탈리아, 56126
- A.O. Universitaria Pisana
-
-
Veneto
-
Cona (Ferrara), Veneto, 이탈리아, 44124
- Azienda Ospedaliero-Universitaria Di Ferrara Arcispedale Santanna
-
Padova, Veneto, 이탈리아, 35128
- Uni Di Padova
-
-
-
-
-
Prague, 체코, 128 50
- Revmatologicky Ustav
-
-
-
-
-
Arequipa, 페루, 04000
- Hogar Clínica San Juan de Dios
-
Lima, 페루
- Instituto de Ginecología y Reproducción
-
Lima, 페루, 15431
- Clínica San Juan Bautista CSJB
-
San Isidro, 페루, L27 Lima
- Clinica El Golf
-
Trujillo, 페루, 13008
- Clinica San Antonio;Investigaciones Trujillo S.A.C.
-
-
-
-
-
Bydgoszcz, 폴란드, 85-168
- Szpital Uniwersytecki
-
Poznan, 폴란드, 61-397
- Prywatna Praktyka Lekarska
-
Poznan, 폴란드, 61-545
- Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM
-
Poznan, 폴란드, 60-218
- Medyczne Centrum Hetmanska
-
Warsaw, 폴란드, 02-118
- Rheuma Medicus Zaklad Opieki Zdrowotnej
-
Warsaw, 폴란드, 00-874
- MICS Centrum Medyczne Warszawa
-
Wroc?aw, 폴란드, 52-210
- REUMATOP Grzegorz Rozumek, Karin Pistorius Spó?ka Jawna
-
-
-
-
-
Paris, 프랑스, 75651
- Ch Pitie Salpetriere
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria >=12 weeks prior to screening
- Anti-nuclear antibody (ANA) >=1:80, or anti-dsDNA and/or anti-Sm antibodies above the upper limit of normal (ULN), as determined by the central laboratory at screening
- Low C3 or low C4 or low CH50 complement as determined by the central laboratory at screening
- High disease activity at screening, based on; BILAG-2004 (Category A disease in >=1 organ system and/or Category B disease in >=2 organ systems), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (score >=8) and Physician's Global Assessment (PGA) (score >=1.0 on a 0 to 3 visual analogue scale [VAS])
- High disease activity on Day 1, based on; SLEDAI-2K (score >=8) and PGA (score >=1.0 on a 0 to 3 VAS)
- Current receipt of >=1 of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroid (OCS), antimalarials, conventional immunosuppressants
- Other inclusion criteria may apply
- The Medical Monitor may be consulted if there are any questions related to eligibility criteria
Exclusion Criteria:
- Pregnancy or breastfeeding
- Presence of significant lupus-associated renal disease and/or renal impairment
- Receipt of an excluded therapy, including any anti-CD20, anti-CD19 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
- Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
- Known active infection of any kind or recent major episode of infection
- Intolerance or contraindication to study therapies
- Other exclusion criteria may apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Obinutuzumab
Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26. |
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
다른 이름들:
Acetaminophen 650-1000 mg will be administered as premedication prior to infusions. Diphenhydramine 50 mg will be administered as premedication prior to infusions. Methylprednisolone 80 mg IV will be administered as premedication prior to infusions. |
|
위약 비교기: Placebo
Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26. |
Acetaminophen 650-1000 mg will be administered as premedication prior to infusions. Diphenhydramine 50 mg will be administered as premedication prior to infusions. Methylprednisolone 80 mg IV will be administered as premedication prior to infusions. Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52
기간: At Week 52
|
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); 2) No new systems or organs affected, as defined by >=1 new British Isles Lupus Assessment Group (BILAG) A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point Physician's Global Assessment-Visual Analog Scale (PGA-VAS). SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52
기간: At Week 52
|
Achieving BICLA was defined as all of the following: 1) Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No net increase in SLEDAI-2K score from baseline; 4) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52
기간: From Week 40 through Week 52
|
Sustained OCS was defined as all of the following: 1) No treatment with prednisone >7.5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders. |
From Week 40 through Week 52
|
|
Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52
기간: From Week 40 Through Week 52
|
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
From Week 40 Through Week 52
|
|
Percentage of Participants With SRI(6) Response at Week 52
기간: At Week 52
|
Achieving SRI(6) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Time to BILAG Flare Over 52 Weeks
기간: At Week 52
|
BILAG flare was defined as the occurrence of >=1 new BILAG A or >=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and lack of efficacy (regardless of discontinuation from treatment or study) were considered as having a flare at the time of the event. Participants who experienced early discontinuation from the blinded period due to reasons other than lack of efficacy and those who completed 52 week treatment period without flare were censored at the time of the event. Kaplan-Meier (KM) method was used to estimate the time to first BILAG flare. |
At Week 52
|
|
Percentage of Participants Who Achieved SRI(4) at Week 24
기간: At Week 24
|
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 24
|
|
Percentage of Participants Who Achieved Clinical SRI(4) at Week 52
기간: At Week 52
|
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of >=4 points in the SLEDAI-2K, excluding points from the immunologic components (low complement and elevated anti-dsDNA antibody; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids
기간: At Week 52
|
Achieving SRI(4) on low doses of corticosteroids was defined as all of the following: 1) Reduction from baseline of >=4 points in SLEDAI-2K; 2) No new systems or organs affected, as defined by >=1 new BILAG A or >=2 new BILAG B items compared with baseline; 3) No worsening from baseline of >=0.30 points on a 3-point PGA-VAS; 4) Prednisone <=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52
기간: At Week 52
|
LLDAS response was defined as achievement of all of the following: 1) SLEDAI-2K <=4; 2) No SLEDAI-2K activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no BILAG hemolytic anemia or gastrointestinal activity; 3) No new SLEDAI-2K activity compared with the previous assessment PGA-VAS <=1; 4) Current prednisone dose <=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). |
At Week 52
|
|
Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52
기간: At Week 52
|
DORIS response was defined as achievement of all of the following: 1) Clinical SLEDAI-2K (cSLEDAI-2K) = 0, where cSLEDAI-2K is defined as total SLEDAI-2K score excluding anti-dsDNA and complement items; 2) PGA-VAS <0.5; 3) Current prednisone dose <=5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE, were considered nonresponders. |
At Week 52
|
|
Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52
기간: Baseline, Weeks 24 and 52
|
The FACIT-F was a patient-completed questionnaire consisting of 13 items that assessed fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as: 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Adjusted mean values have been reported. The analysis was performed using analysis of covariance (ANCOVA) model. |
Baseline, Weeks 24 and 52
|
|
Change in 36-Item Short Form Survey, Version 2 (SF-36 V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52
기간: Baseline, Weeks 24 and 52
|
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model. |
Baseline, Weeks 24 and 52
|
|
Change in SF-36 V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52
기간: Baseline, Weeks 24 and 52
|
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and the MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model. |
Baseline, Weeks 24 and 52
|
|
Change in Active Joint Count From Baseline to Weeks 24 and 52
기간: Baseline, Weeks 24 and 52
|
Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Data after the first occurrence of intercurrent event (ICE), including major concomitant therapy violation, treatment failure requiring rescue medication or early discontinuation from the blinded period due to AE, death and lack of efficacy, was imputed using the worst post-baseline value from the following assessments: the last value available prior to the occurrence of the first ICE; all values available after the occurrence of the ICE. Participants with treatment discontinuation without any ICE above were evaluated under the treatment policy strategy. Adjusted mean values have been reported. The analysis was performed using ANCOVA model. |
Baseline, Weeks 24 and 52
|
|
Percentage of Participants Who Achieved a >=50% Reduction in Active Joint Counts at Each Study Visit, Among Participants With >=4 Active Joints at Baseline
기간: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
|
Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders. |
At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
|
|
Percentage of Participants Who Achieved a >=50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at Each Study Visit
기간: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
|
CLASI is a validated instrument for assessing cutaneous lupus erythematosus activity. It reports two global scores: one for current inflammatory activity (Total Activity Score), and one for damage (Total Damage Score). To calculate the total scores, trained assessors evaluate erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis at 13 anatomic locations plus additional assessments for mucosal lesions and alopecia. CLASI total activity score ranges from 0 to 70, with higher scores indicating increased disease severity. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders. |
At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
|
|
Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52
기간: From Week 40 through Week 52
|
Sustained OCS was defined as all of the following: 1) No treatment with prednisone >5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders. |
From Week 40 through Week 52
|
|
Cumulative Corticosteroid Use Through Week 52
기간: Up to Week 52
|
Cumulative oral corticosteroid was represented in prednisone or equivalent only. The mean of the standardized area under the curve (AUC) through Week 52 have been reported. AUC was derived based on the actual dose participants have received. Standardized AUC was derived using AUC divided by days in study multiplied by 365.25 days for each participant. |
Up to Week 52
|
|
Annualized Flare Rate Through Week 52
기간: Up to Week 52
|
BILAG flare was defined as the occurrence of >=1 new BILAG A or >=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). The number of flares over the 52-week blinded treatment period has been reported. The number is calculating rate, which is the number of events (flares) over total participant-years (time period). |
Up to Week 52
|
|
Number of Participants With Adverse Events (AEs)
기간: Up to Week 52
|
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. |
Up to Week 52
|
|
Number of Participants With Adverse Events of Special Interests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and Thrombocytopenia
기간: Up to Week 52
|
AESIs for this study were as follows: cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by a study treatment (Hy's Law); IRRs (systemic IRRs only); grade >=3 infections; any hepatitis B reactivation; progressive multifocal leukoencephalopathy (PML); study drug-related neutropenia; study drug-related thrombocytopenia; gastrointestinal (GI) perforations; worsening of preexisting cardiac conditions. |
Up to Week 52
|
|
Maximum Serum Concentration (Cmax) of Obinutuzumab
기간: From Weeks 0-24 and Weeks 24-52
|
Cmax is defined as the maximum concentration of a drug in the serum. Cmax is reported at steady state. Hence, only one value for the specified assessment periods is reported here. |
From Weeks 0-24 and Weeks 24-52
|
|
Trough Concentration (Ctrough) of Obinutuzumab
기간: From Weeks 0-24 and Weeks 24-52
|
Ctrough is defined as the concentration immediately prior to the next dose at steady state (end of the dosing interval). Data were collected when the participant attended the next dose administration visits over the two time intervals. |
From Weeks 0-24 and Weeks 24-52
|
|
Area Under the Concentration-time Curve (AUC) of Obinutuzumab
기간: Week 0-52
|
AUC is defined as the area under the drug concentration-time curve and represents drug exposure over a specified time interval. Data presented here give exposure over the duration of 0 to 52 weeks. |
Week 0-52
|
|
Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab
기간: Up to Week 52
|
Participants who received obinutuzumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following obinutuzumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here. |
Up to Week 52
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Clinical Trials, Hoffmann-La Roche
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- CA42750
- 2020-005760-57 (EudraCT 번호)
- 2023-504774-38-00 (기타 식별자: EU CT Number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .